AIM: Capecitabine, a 5-fluorouracil prodrug, has been integrated into the management of multiple cancer types. In order to obtain information about plasma levels of capecitabine in patients who had drug intake at home during chemotherapy, a simple HPLC method for capecitabine monitoring has been developed and validated. PATIENTS AND METHODS: Capecitabine levels were quantified by a simple reversed-phase HPLC system with an external standard method. Plasma samples were obtained from 12 colorectal cancer patients who underwent chemotherapy with capecitabine alone (1000 mg/m(2)) or combined with oxaliplatin (130 mg/m(2)). RESULTS: Although there was evidence that capecitabine had not been taken according to the chemotherapeutic schedule in two cases, the study demonstrated that its combination with oxaliplatin showed no significant drug-drug interactions. CONCLUSION: Due to its robustness, specificity and sensitivity, the method is also well-suited for capecitabine analysis in other pharmacokinetic studies.
AIM: Capecitabine, a 5-fluorouracil prodrug, has been integrated into the management of multiple cancer types. In order to obtain information about plasma levels of capecitabine in patients who had drug intake at home during chemotherapy, a simple HPLC method for capecitabine monitoring has been developed and validated. PATIENTS AND METHODS: Capecitabine levels were quantified by a simple reversed-phase HPLC system with an external standard method. Plasma samples were obtained from 12 colorectal cancerpatients who underwent chemotherapy with capecitabine alone (1000 mg/m(2)) or combined with oxaliplatin (130 mg/m(2)). RESULTS: Although there was evidence that capecitabine had not been taken according to the chemotherapeutic schedule in two cases, the study demonstrated that its combination with oxaliplatin showed no significant drug-drug interactions. CONCLUSION: Due to its robustness, specificity and sensitivity, the method is also well-suited for capecitabine analysis in other pharmacokinetic studies.
Authors: Christian Dittrich; Robert Königsberg; Martina Mittlböck; Klaus Geissler; Azra Sahmanovic-Hrgovcic; Johannes Pleiner-Duxneuner; Martin Czejka; Philipp Buchner Journal: Invest New Drugs Date: 2018-07-12 Impact factor: 3.850